This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
marijuana: Archive
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
by Sundeep Ganoria
HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.
JAZZNegative Net Change AXSMPositive Net Change HRMYPositive Net Change
biotechs marijuana medical
Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?
by Sundeep Ganoria
CURLF dives 46% YTD as domestic headwinds outweigh global growth; is it time to cash out or wait for a rebound?
CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change CURLFPositive Net Change
marijuana medical pot-stocks
Could the New Federal Bill Derail the U.S. Hemp Industry?
by Sundeep Ganoria
A proposed federal bill could upend the U.S. hemp market, threatening CBD and Delta-8 products now sold nationwide.
CGCPositive Net Change TLRYPositive Net Change CURLFPositive Net Change
marijuana medical pot-stocks
Cannabis Stock CGC Rallies 39% in Three Months: Time to Buy or Sell?
by Sundeep Ganoria
Canopy Growth surges 39% in three months as restructuring, margin gains and debt cuts renew investor interest.
CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change VFFPositive Net Change
marijuana medical pot-stocks
Cannabis Operator VFF Sells Fresh Produce Unit: How to Play the Stock?
by Sundeep Ganoria
After dropping its produce business, Village Farms sharpens its cannabis focus - boosting exports, margins and market share.
CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change VFFPositive Net Change
marijuana medical pot-stocks
Aurora Cannabis Stock Rises 30% YTD: Time to Buy or Sell?
by Sundeep Ganoria
ACB's 30% YTD rally reflects Q3 strength, but flat EPS estimates and consumer weakness keep analysts cautious about long-term upside.
CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change
marijuana medical pot-stocks
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
by Sundeep Ganoria
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
NVONegative Net Change LLYPositive Net Change CRBPNegative Net Change SKYEPositive Net Change
biotechs marijuana medical pharmaceuticals
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
by Sundeep Ganoria
While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.
SNYNegative Net Change NVONegative Net Change CRBPNegative Net Change
marijuana medical
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?
by Sundeep Ganoria
TLRY's pivot into beverages shows promise, but with falling cannabis sales and delisting risks, we recommend staying on the sidelines for now.
PMPositive Net Change JAZZNegative Net Change CRBPNegative Net Change TLRYPositive Net Change
marijuana medical pot-stocks
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
by Zacks Equity Research
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
JAZZNegative Net Change PBYIPositive Net Change NTLAPositive Net Change ELEVPositive Net Change
biotechs cannabis earnings marijuana medical pharmaceuticals
IIPR's Q1 Earnings Coming Up: Key Factors to Impact the Stock
by Zacks Equity Research
IIPR's Q1 2025 results may be impacted by property repossessions/sales, rent deferrals and partial tenant payments.
IIPRNegative Net Change LAMRNegative Net Change EPRPositive Net Change
cannabis finance marijuana reit
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
JAZZNegative Net Change AMRXPositive Net Change
biotechs cancer cannabis earnings-preview marijuana medical
3 Unconventional Cannabis Stocks to Watch in 2025
by Sundeep Ganoria
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
PMPositive Net Change JAZZNegative Net Change CRBPNegative Net Change
biotechs marijuana medical pharmaceuticals pot-stocks
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
by Sundeep Ganoria
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.
JAZZNegative Net Change KNSAPositive Net Change CRDLPositive Net Change
biotechs marijuana medical pot-stocks
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
by Sundeep Ganoria
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
JAZZNegative Net Change HRMYPositive Net Change
biotechs cannabis marijuana marijuana-stocks medical pharmaceuticals
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?
by Sundeep Ganoria
Not your typical cannabis play. Discover why Jazz Pharma's FDA-approved CBD drug could make it a top cannabis stock to watch in 2025.
JAZZNegative Net Change TLRYPositive Net Change
biotechs marijuana medical pot-stocks
Best & Worst ETF Zones of Q1
by Sweta Killa
We have highlighted three ETFs, each from the best and worst-performing zones in the first quarter of 2025.
EPOLPositive Net Change SGDMPositive Net Change WGMIPositive Net Change WEEDNegative Net Change EETHNegative Net Change BABONegative Net Change
bitcoin etfs gold marijuana
Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?
by Urmimala Biswas
ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.
CGCPositive Net Change ACBPositive Net Change OGIPositive Net Change
cannabis healthcare marijuana marijuana-stocks medical
IIPR's Q4 Earnings Coming Up: Key Factors to Impact the Stock
by Zacks Equity Research
Innovative Industrial's Q4 performance is likely to have been affected by a decline in contractual rent and property management fees and elevated expenses.
RHPNegative Net Change IIPRNegative Net Change PKPositive Net Change
cannabis finance marijuana reit
Is IIPR Stock a Buy, Hold or Sell After Its 49% Plunge in 3 Months?
by Moumita C. Chattopadhyay
With a volatile cannabis market and tenant risks, is IIPR's high yield sustainable, or will challenges overshadow its growth?
PLDNegative Net Change TRNOPositive Net Change IIPRNegative Net Change
cannabis finance marijuana marijuana-stocks reit
Top & Flop ETFs of 2024
by Sweta Killa
We have highlighted three ETFs each from the best and worst-performing zones in 2024.
TSLANegative Net Change ARGTPositive Net Change GBTCNegative Net Change MAGSPositive Net Change BDRYPositive Net Change WEEDNegative Net Change ILITPositive Net Change
bitcoin etfs marijuana tech-stocks
Markets Up Ahead of CPI, Jobless Claims Thursday
by Mark Vickery
The Inflation Rate, which is CPI year over year headline, is expected to come down 20 basis points from +2.5% to +2.3%.
DALPositive Net Change AANegative Net Change DPZNegative Net Change TLRYPositive Net Change
agriculture airlines consumer-discretionary consumer-staples marijuana restaurants
Best and Worst ETF Zones of Q2
by Sweta Killa
Technology remained the best-performing sector of the second quarter on the AI drive while energy lagged.
SLVPPositive Net Change UNGNegative Net Change BDRYPositive Net Change PSILPositive Net Change WGMIPositive Net Change WEEDNegative Net Change
biotechnology bitcoin etfs marijuana
Innovative Industrial (IIPR) Expands With Florida Asset
by Zacks Equity Research
Innovative Industrial's (IIPR) Florida property buyout and tie-up with a subsidiary of AYR Wellness are to help this REIT bank on solid opportunities in the company's markets.
AMTNegative Net Change LAMRNegative Net Change IIPRNegative Net Change
finance marijuana reit
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
by Zacks Equity Research
Cresco Labs' (CRLBF) rationalization and optimization efforts are expected to have had a positive impact on the company's first-quarter margins, profitability and cash flow.
ALCNegative Net Change GRTSNo Net Change ERASNegative Net Change CRLBFNegative Net Change
earnings marijuana medical